HRTX stock forecast, quote, news & analysis
Heron Therapeutics Inc is a commercial-stage biotechnology company... Show more
Why Heron Therapeutics (HRTX) Stock Is Down -28% in the Last 30 Days
Key Takeaways
- Heron Therapeutics (HRTX) shares declined roughly 28% over the last 30 days, falling from a $0.4061 close on October 9, 2026 to $0.293 on November 6, 2026.
- The pullback extends a longer downturn: the stock is down about 40% over the trailing quarter after trading near $0.51 in early August.
- The dominant overhang is a June 2026 U.S. District Court ruling on certain CINVANTI patents, which raised the risk of generic competition; Heron has filed an appeal.
- Management withdrew full-year 2026 guidance and is reviewing strategic alternatives while tightening spending to preserve liquidity.
- Acute care products ZYNRELEF and APONVIE continue to grow, but CINVANTI—the company's largest revenue contributor—faces branded and potential generic pressure.
- Third-quarter 2026 financial results are scheduled to be reported on November 9, 2026.
- For additional details, explore Heron's Price Targets, Earnings, and Forecast pages.
- Traders seeking automated signals can also explore Trending AI Robots for data-driven strategies across thousands of tickers.
Heron Therapeutics (HRTX) Company Overview and Market Position
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing therapeutics for acute care and oncology patients. Its acute care portfolio includes ZYNRELEF, a dual-acting extended-release local anesthetic combining bupivacaine and low-dose meloxicam for postoperative pain, and APONVIE, an intravenous aprepitant formulation for the prevention of postoperative nausea and vomiting. In oncology, the company markets CINVANTI, an intravenous aprepitant for chemotherapy-induced nausea and vomiting, while SUSTOL, an extended-release granisetron product, was withdrawn from the market as of September 30, 2026.
Investors follow HRTX because of its growing acute care franchise and its established oncology cash flows. ZYNRELEF and APONVIE have delivered strong year-over-year growth, but CINVANTI remains the company's largest single revenue source, which makes patent and competitive developments a key swing factor for the stock.
Heron Therapeutics (HRTX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, HRTX fell from a closing price of $0.4061 on October 9, 2026 to $0.293 on November 6, 2026, a decline of approximately 27.9%, or about 28%. The shares gave back an early-October rebound that had carried them back above the $0.40 level, before renewed selling pressure pushed the stock toward the $0.28 to $0.30 range by early November.
The quarterly trend tells a similar but steeper story. After closing near $0.51 in early August 2026, the stock dropped sharply in mid-August—coinciding with second-quarter results and the withdrawal of full-year guidance—and has since trended lower. Over roughly three months, the shares have declined approximately 40%, reflecting sustained investor caution rather than a single isolated event.
What Drove HRTX Stock Price in the Last 30 Days
The 30-day decline was driven less by one discrete catalyst than by the market's continued reassessment of risks that emerged earlier in 2026. The most significant factor remains the June 2026 U.S. District Court decision concerning certain CINVANTI patents, which introduced uncertainty around the timing and terms of potential generic competition for the company's top-selling product. Heron has appealed the ruling, but until the appeal is resolved, the loss-of-exclusivity risk weighs on sentiment.
That legal uncertainty prompted management to withdraw its full-year 2026 guidance for net product sales and adjusted EBITDA and to announce a review of strategic alternatives. The company also amended its credit facility, agreeing to staged principal reductions that reduced its pro forma cash position. These liquidity considerations have kept investors cautious. The stock's inability to hold its early-October bounce, combined with modest insider selling disclosed in late October and positioning ahead of the November 9 third-quarter report, contributed to the slide toward the $0.29 level.
What Drove HRTX Stock Performance Over the Last Quarter
The broader three-month decline traces back to the August 10, 2026 selloff, when shares fell sharply after second-quarter results and management's decision to withdraw full-year guidance following the CINVANTI court ruling. Although Heron reported solid momentum in acute care—ZYNRELEF net sales up 35% year-over-year and APONVIE up 74%—the oncology franchise, anchored by CINVANTI, declined roughly 16% year-over-year due to branded competition.
Liquidity has been a recurring theme. The company ended the second quarter with $42.7 million in cash, cash equivalents, and short-term investments, but pro forma cash was materially lower after credit-facility principal reductions. The combination of legal risk, withdrawn guidance, and a tighter balance sheet has kept the stock under pressure for most of the quarter, even as acute care demand metrics continued to improve.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots from a broader platform that offers hundreds of bots trading thousands of tickers. Only the top-performing and most relevant bots appear in this section, each operating with its own strategy, timeframe, and performance metrics. Because the bots vary widely in approach, investors can compare different styles and objectives rather than relying on a single signal. For those following names such as HRTX, exploring this section can provide a complementary, data-driven perspective on market activity.
HRTX Stock Forecast Drivers: What Investors Should Watch Next
The most immediate catalyst is the third-quarter 2026 earnings report and conference call scheduled for November 9, 2026, which should clarify recent revenue trends, cash and covenant compliance, and any updates on the strategic alternatives review. Investors will also monitor the progress of Heron's appeal of the CINVANTI patent ruling, since any ruling on generic entry timelines could materially affect the company's largest revenue stream.
Beyond legal developments, key factors include the continued commercial ramp of ZYNRELEF and APONVIE, gross margin trends, and the company's ability to manage its balance sheet and credit-facility covenants. Demand for CINVANTI and any competitive or reimbursement changes in the oncology and surgical markets also remain important. As always, these factors should be evaluated in the context of each investor's own objectives and risk tolerance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
HRTX in +32.36% Uptrend, advancing for three consecutive days on November 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where HRTX advanced for three days, in 181 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 60 cases where HRTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on HRTX as a result. In 65 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for HRTX just turned positive on November 09, 2026. Looking at past instances where HRTX's MACD turned positive, the stock continued to rise in 31 of 39 cases over the following month. The odds of a continued upward trend are 79%.
HRTX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The Aroon Indicator entered an Uptrend today. In 113 of 141 cases where HRTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The 10-day moving average for HRTX crossed bearishly below the 50-day moving average on October 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
HRTX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.496) is normal, around the industry mean (3.498). P/E Ratio (-1.542) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.387) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. HRTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HRTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of polymer technologies
Industry Biotechnology